EGFR and cholangiocarcinoma: Blocking EGFR degradation induces the proliferation of CC cells through prolonged EGFR activation-mediated COX-2/prostaglandin (PGE2) signaling relative to other hepatoma cells, and PGE2 as a downstream product of COX-2 prevents EGFR inhibitor-mediated growth suppression in CC cells [80].